Cyclic Peptides: Design, Synthesis, and Drug Discovery Applications

Cyclic peptides are peptide molecules in which part or all of the sequence is constrained by a covalent linkage. Depending on the design, the ring may connect the N- and C-termini, two side chains, a terminus and a side chain, or other chemically introduced functional groups.

This structural constraint can change how a peptide behaves in solution and in biological systems. Ring formation may alter conformational flexibility, proteolytic stability, target-binding geometry, membrane permeability, solubility, and synthetic accessibility. These properties have made cyclic and macrocyclic peptides increasingly important in chemical biology, peptide drug discovery, and the study of challenging molecular targets such as protein-protein interactions.

Cyclization does not automatically improve a peptide. The effect depends on the sequence, ring size, linkage chemistry, cyclization position, and the three-dimensional arrangement of residues required for biological activity.

For research projects, cyclic peptide design is therefore best approached as a structural optimization problem rather than as a routine modification added after a linear sequence has already been selected.

What Is a Cyclic Peptide?

A cyclic peptide contains at least one covalent connection that forms a closed molecular ring. The resulting structure may involve the peptide backbone, amino-acid side chains, or both.

Common cyclic peptide architectures include:

• head-to-tail backbone cyclization

• disulfide-bond cyclization between cysteine residues

• side-chain lactam formation, such as Lys-Asp or Lys-Glu linkage

• thioether-containing rings

• chemoselective or noncanonical macrocyclization strategies

The term macrocyclic peptide is widely used in medicinal chemistry for larger cyclic peptide structures. In practice, the field includes molecules ranging from relatively simple disulfide-constrained peptides to highly engineered macrocycles containing D-amino acids, N-methylated residues, noncanonical amino acids, backbone modifications, or nonpeptidic structural elements.

For a more detailed comparison of individual ring-closing chemistries, see Peptide Cyclization Strategies.

How Cyclization Changes Peptide Conformation

Linear peptides can often adopt many conformations in solution. Only a subset of those conformations may be compatible with binding to a receptor, enzyme, antibody, or protein surface.

A cyclic constraint reduces the conformational space available to the peptide. When the ring geometry is compatible with the bioactive conformation, the target-binding residues may become more consistently presented in a productive orientation.

This preorganization can influence binding affinity and selectivity by changing the energetic cost associated with adopting the bound state. The effect is strongly sequence- and structure-dependent.

A constraint introduced at an unsuitable position can distort the pharmacophore, create steric strain, reduce binding, or produce a peptide that becomes harder to synthesize and purify.

We therefore treat peptide cyclization as a form of conformational engineering. The objective is to stabilize a useful molecular geometry without disrupting the residues responsible for biological recognition.

Cyclic Peptides Versus Linear Peptides

The difference between a linear and cyclic peptide is not limited to molecular shape. Ring formation can change several experimentally important properties simultaneously.

These are general tendencies rather than universal rules. A cyclic analogue may gain proteolytic stability while losing receptor affinity, or improve binding while becoming less soluble.

When a peptide is being cyclized for the first time, comparing matched linear and cyclic analogues can therefore provide more useful information than assuming the cyclic form will perform better.

Why Cyclic Peptides Are Useful for Protein-Protein Interactions

Protein-protein interactions are an important application area for cyclic peptides. Many PPI interfaces are broad, relatively flat, and dynamic, with fewer deep binding pockets than conventional small-molecule targets.

Peptides can contact a larger surface area and reproduce several residues from a natural protein-binding motif. Cyclization can then constrain those residues into a defined spatial arrangement.

This creates a useful combination of molecular recognition and chemical tunability. Individual residues can be substituted, stereochemistry changed, noncanonical amino acids introduced, or ring geometry modified while retaining the overall interaction motif.

Recent research continues to expand this area. A 2026 review of macrocyclic peptide PPI modulators highlighted conformational constraint, proteolytic stability, target affinity, and selected improvements in cell permeability as important properties driving development of this molecular class.

For researchers starting from a known linear binding sequence, structural information can be particularly valuable. Residues that appear close in the primary sequence are not necessarily close in the target-bound conformation. Cyclization sites should therefore be evaluated in three-dimensional context whenever structural data are available.

Can Cyclic Peptides Reach Intracellular Targets?

Cell permeability remains one of the central challenges in peptide drug discovery.

Some cyclic peptides can cross biological membranes substantially more efficiently than comparable linear peptides. This behavior is associated with a combination of molecular size, polarity, charge, hydrophobicity, ring conformation, backbone chemistry, and intramolecular hydrogen bonding.

In selected macrocycles, intramolecular hydrogen bonds can reduce the apparent polarity of the peptide by shielding hydrogen-bond donors and acceptors from the surrounding environment. Conformational changes between aqueous and membrane-like environments may also contribute to permeability.

Cyclization itself is not sufficient. Highly charged or strongly polar cyclic peptides may still show poor passive membrane transport.

A 2026 Nature Chemical Biology study provides a useful experimental example. Researchers screened 15,360 fully random cyclic peptides and identified inhibitors of the Keap1-Nrf2 protein-protein interaction. Subsequent design-build-test optimization produced a membrane-permeable cyclic compound that was active in live cells.

The study is important because it shows that permeability can emerge from coordinated optimization of sequence, ring architecture, physicochemical properties, and target binding rather than from cyclization alone.

How Cyclization Can Affect Proteolytic Stability

Proteolytic degradation is another common limitation of linear peptides.

Head-to-tail cyclization eliminates the free N- and C-termini and can reduce susceptibility to exopeptidases. Side-chain and disulfide constraints may also reduce access to internal cleavage sites by limiting local flexibility.

The resulting stability improvement depends on the protease, sequence, ring size, backbone accessibility, stereochemistry, and biological matrix.

A cyclic peptide should therefore be tested under conditions relevant to the intended experiment when stability is an important performance parameter.

We do not recommend using “cyclic” as a substitute for an actual stability experiment. Serum stability, plasma stability, intracellular stability, and digestive-enzyme stability represent different biological environments and can produce different results.

How Cyclic Peptide Libraries Are Used in Discovery

Modern cyclic peptide discovery extends well beyond converting an existing linear peptide into a ring.

Phage display, mRNA display, genetically encoded libraries, chemically synthesized libraries, and other high-diversity screening technologies can explore large cyclic peptide sequence spaces directly.

These approaches allow researchers to identify ligands without first knowing the exact peptide sequence or cyclization geometry required for binding.

Library-based discovery is particularly useful for difficult protein surfaces and PPI targets because many different combinations of sequence, ring size, stereochemistry, and side-chain chemistry can be evaluated experimentally.

The 15,360-member synthetic library reported in 2026 is one example at a relatively focused scale. Other display-based technologies can access far larger sequence spaces, while smaller synthetic libraries can provide tighter control over noncanonical chemistry and direct structure-activity studies.

The most appropriate discovery format depends on the target, available structural information, chemical diversity required, screening assay, and the number of candidates that can realistically be synthesized and validated.

2026 Marked an Important Step for Oral Macrocyclic Peptides

Two U.S. approvals in 2026 provide useful evidence of how extensively macrocyclic peptide properties can be engineered.

On March 17, 2026, the U.S. FDA approved icotrokinra (ICOTYDE) for moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy.

Icotrokinra is a chemically synthesized macrocyclic peptide targeting the IL-23 receptor. A 2024 Scientific Reports study reported a molecular weight of 1898.19 g/mol and a mean dissociation constant (K_D) of 7.1 pM for binding to the human IL-23 receptor extracellular domain at 37 °C.

The FDA reported that the ICOTYDE approval was supported by four randomized, double-blind, placebo-controlled trials involving 2,500 participants. The drug is administered orally once daily.

On July 15, 2026, the FDA approved Lipfendra (enlicitide decanoate) to reduce LDL cholesterol in adults with hypercholesterolemia. The FDA described it as the first oral therapy to inhibit PCSK9.

Its efficacy and safety were evaluated in two randomized, double-blind, placebo-controlled trials involving 3,207 adults. At Week 24, the FDA reported average placebo-adjusted LDL-C reductions of 56% in the first trial and 59% in the heterozygous familial hypercholesterolemia trial.

These examples should not be interpreted as evidence that ordinary cyclization produces oral bioavailability.

The medicinal chemistry program that produced enlicitide addressed multiple properties including potency, oxidation liability, solubility, stability, pharmacokinetics, structural complexity, synthesis, and manufacturability.

Oral macrocyclic peptide development is therefore a multi-parameter optimization problem. Ring formation provides a structural framework, but sequence composition, backbone chemistry, stereochemistry, polarity, intramolecular hydrogen bonding, and physicochemical properties remain critical.

How Cyclic Peptides Are Synthesized

Many synthetic cyclic peptides begin as linear precursors assembled by solid-phase peptide synthesis (SPPS).

The ring-forming reaction may be performed while the peptide remains attached to the resin or after cleavage, depending on the sequence, linkage chemistry, protecting-group strategy, and desired architecture.

Common approaches include disulfide formation, head-to-tail amide formation, side-chain lactamization, thioether formation, native chemical ligation, and other chemoselective reactions.

Macrocyclization can become a major synthetic challenge because the desired intramolecular reaction competes with intermolecular reactions that can generate dimers or higher oligomers.

Reaction efficiency may be affected by:

• ring size and conformational strain

• distance and orientation of the reactive groups

• peptide concentration

• sequence hydrophobicity and aggregation

• steric accessibility

• protecting-group strategy

• solvent and coupling chemistry

For routine research projects, the most elaborate cyclization method is not necessarily the most useful. We favor a strategy that is compatible with the biological objective, chemically reproducible, and analytically distinguishable from major side products.

Ring Size Is Part of the Biological Design

Ring size influences both synthetic feasibility and peptide conformation.

A short ring can create excessive strain or force key residues away from the orientation required for binding. A larger ring may reduce strain but retain enough flexibility that relatively little conformational stabilization is gained.

This is particularly important when a known linear peptide is being converted into a cyclic analogue.

Choosing two residues simply because they are separated by a convenient number of amino acids does not ensure that they occupy compatible positions in three-dimensional space.

When a peptide-target structure, NMR model, cryo-EM structure, crystallographic complex, or reliable structural hypothesis is available, candidate cyclization sites can be evaluated against the geometry of the bound peptide.

Disulfide-Cyclic Peptides Need Connectivity Control

Disulfide bonds are common structural elements in peptide hormones, toxins, signaling molecules, and other biologically active peptides.

A single intramolecular Cys-Cys bridge can provide an effective and biologically familiar constraint.

Projects containing several cysteine residues are more complicated because alternative disulfide pairings may generate structural isomers.

These isomers can have the same molecular mass while adopting different three-dimensional structures and biological activities.

Mass spectrometry alone therefore cannot establish the connectivity of a peptide containing multiple possible disulfide arrangements.

When a specific disulfide pattern is essential to the biological question, the analytical plan should be selected accordingly rather than relying only on nominal HPLC purity and molecular mass.

What Does HPLC/MS Tell You About a Cyclic Peptide?

Quality control is especially important after a cyclization reaction because several chemically related species can be present in the crude material.

Depending on the peptide and cyclization chemistry, these can include:

• uncyclized linear precursor

• desired cyclic product

• deletion or truncated sequences

• oxidation products

• intermolecular dimers or oligomers

• alternative disulfide isomers

• other synthesis-related side products

Analytical HPLC provides information about chromatographic composition and purity. Mass spectrometry provides evidence that the detected molecular mass is consistent with the expected peptide.

The two measurements answer different questions.

For many routine research peptides, analytical HPLC, mass spectrometry, and a Certificate of Analysis provide appropriate baseline quality documentation. More complex cyclic peptides may require additional project-specific characterization when stereochemistry, connectivity, conformational state, or structurally similar isomers are central to the experiment.

We do not consider a higher nominal purity percentage a substitute for confirming that the purified material represents the intended cyclic molecular form.

What Should Researchers Specify Before Ordering a Cyclic Peptide?

A supplier can usually assess a cyclic peptide project more accurately when the biological objective and molecular structure are provided together.

Complete peptide sequence

The full sequence is needed to evaluate synthesis difficulty, reactive residues, hydrophobicity, potential aggregation, and compatible protecting-group strategies.

Cyclization sites and linkage chemistry

If the cyclic architecture is already defined in a publication or previous experiment, the exact linkage should be specified. If it is not defined, the functional role of the peptide and residues that must remain unchanged become especially important.

Required termini

Head-to-tail cyclization consumes both termini. If the N- or C-terminus is required for receptor recognition, labeling, conjugation, or another modification, a side-chain strategy may be more appropriate.

Additional peptide modifications

Fluorescent labels, biotin, lipids, PEG-type spacers, affinity handles, phosphorylation, or other modifications need attachment positions that remain chemically compatible with the ring and do not disrupt the binding surface.

Downstream application

A peptide intended for a biochemical binding assay may have different purity, solubility, modification, and characterization requirements from a peptide intended for intracellular studies, structural biology, screening, or lead optimization.

Researchers with an established sequence can review our Custom Peptide Synthesis capabilities for cyclic peptide synthesis, purification, analytical HPLC, mass spectrometry, and project-specific modifications.

Should You Synthesize One Cyclic Peptide or Several Variants?

When the cyclic structure has already been validated experimentally, reproducing the established architecture may be sufficient.

A new cyclic design presents a different problem.

One cyclic analogue does not reveal whether a negative biological result is caused by cyclization itself or by the specific geometry that was selected.

When assay throughput and project budget permit, we prefer comparing the original linear peptide with a small rational set of cyclic candidates.

Useful variables can include cyclization position, ring size, linker geometry, selected stereochemical changes, and substitutions intended to improve solubility or synthetic accessibility.

This type of panel creates more information from each experiment. If one ring geometry fails while another retains activity, the result begins to define the conformational requirements of the peptide rather than simply producing a positive or negative result.

AI and Structure-Guided Cyclic Peptide Design

Cyclic peptide design increasingly combines structural biology, sequence generation, molecular modeling, physicochemical evaluation, and experimental synthesis.

Computational approaches can help prioritize cyclization positions, compare candidate structures, evaluate sequence variants, and reduce a large design space before synthesis.

Predicted structure or model confidence should not be interpreted as experimental evidence of affinity, stability, permeability, or biological activity.

Alan Scientific's HighFoldAI™ cyclic peptide design platform supports cyclic peptide candidate generation, predicted structural evaluation, physicochemical comparison, and candidate prioritization before experimental synthesis.

For discovery projects, computational ranking is most useful when it reduces a large design space to a chemically realistic set of peptides that can be synthesized and tested experimentally.

Frequently Asked Questions

Are cyclic peptides always more stable than linear peptides?

No. Cyclization can improve proteolytic stability, but the effect depends on sequence, ring geometry, cleavage sites, protease type, and the experimental environment.

Can cyclic peptides enter cells?

Some cyclic peptides can show useful membrane permeability. Small size, limited exposed polarity, intramolecular hydrogen bonding, charge distribution, backbone chemistry, hydrophobicity, and conformational behavior can all influence cell entry. Cyclization alone does not guarantee permeability.

What is the difference between a cyclic peptide and a macrocyclic peptide?

Cyclic peptide is the broader term for peptides containing a covalently constrained ring. Macrocyclic peptide is commonly used in medicinal chemistry for larger cyclic structures and engineered cyclic peptide scaffolds. There is no single universally applied ring-size cutoff used across all peptide literature.

Can any linear peptide be converted into a cyclic peptide?

Many linear sequences can be cyclized chemically, but successful ring formation does not guarantee retention of biological activity. Cyclization geometry, ring strain, functional residues, sequence composition, and synthetic feasibility need to be considered.

Which cyclic peptide synthesis method is best?

No single method is best for every sequence. Disulfide, head-to-tail, lactam, thioether, and other strategies impose different chemical and structural constraints. The intended molecular geometry and biological application should guide the choice.

What purity should I order for a cyclic peptide?

The appropriate purity depends on the downstream experiment. Screening or preliminary biochemical work may have different requirements from quantitative binding studies, structural studies, or advanced biological evaluation. Purity should be considered together with molecular identity and the possibility of cyclic isomers or uncyclized precursor.

Is HPLC and mass spectrometry enough to characterize a cyclic peptide?

For many routine research peptides, HPLC and mass spectrometry provide appropriate baseline quality control. They may not establish disulfide connectivity, stereochemistry, or the identity of structurally similar isomers in more complex cyclic peptides.

Conclusion

Cyclic peptides combine peptide-like molecular recognition with a structural constraint that can change conformation, stability, permeability, target binding, and synthetic behavior.

The same ring that creates a useful bioactive structure can also introduce strain, reduce solubility, complicate purification, or interfere with target recognition if the geometry is poorly chosen.

Cyclic peptide development therefore works best when sequence design, ring architecture, assay requirements, synthesis feasibility, purification, and analytical characterization are considered together.

Recent advances in PPI targeting, membrane-permeable cyclic peptide libraries, AI-assisted design, and orally active macrocyclic therapeutics show how broad the design space has become. Experimental validation remains the step that determines whether a predicted or designed constraint produces a useful molecule.

Alan Scientific supports custom cyclic peptide synthesis using disulfide and head-to-tail cyclization strategies, together with purification, analytical HPLC, mass spectrometry, and project-specific modification options.

References

1. Hayes HC, Luk LYP, Tsai YH. Approaches for peptide and protein cyclisation. Organic & Biomolecular Chemistry. 2021;19:3983–4001. doi:10.1039/D1OB00411E.

2. Ji X, Nielsen AL, Heinis C. Cyclic Peptides for Drug Development. Angewandte Chemie International Edition. 2024;63:e202308251. doi:10.1002/anie.202308251.

3. Sunny EA, Sadanandan S. Macrocyclic peptides as protein-protein interaction modulators: a review. Organic & Biomolecular Chemistry. 2026;24:3613–3635. doi:10.1039/D6OB00106H.

4. Ji X, Farrera-Soler L, Li J, et al. Generation of membrane-permeable cyclic peptides inhibiting protein-protein interaction. Nature Chemical Biology. 2026;22:1351–1361. doi:10.1038/s41589-026-02237-7.

5. Fourie AM, Cheng X, Chang L, et al. JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans. Scientific Reports. 2024;14:17515.

6. Josien H, Nair AG, Ding FX, et al. Discovery Process of Enlicitide, a Highly Engineered Macrocyclic Peptide Therapeutic, through Issue-Driven Fragment-Based Synthetic Assembly and SAR. Journal of Medicinal Chemistry. 2026;69:13473–13491. doi:10.1021/acs.jmedchem.6c00463.

7. U.S. Food and Drug Administration. Drug Trials Snapshots: ICOTYDE. Original approval date: March 17, 2026.

8. U.S. Food and Drug Administration. Novel Drug Approvals for 2026: Lipfendra (enlicitide decanoate). Original approval date: July 15, 2026.